More Resources | Manufacturer Actions | Eli Lilly /AstraZeneca

Eli Lilly/AstraZeneca have recently sent notifications to Covered Entities in regard to 340B availability and/or pricing of their products at contract pharmacies.

We are aware of the challenge this presents for your care organization and are actively working on solutions that will continue to help you manage your 340B program during these unprecedented times.

These actions mean that you may notice a pricing change in the 340B catalog. Wholesalers may place the Wholesale Acquisition Cost (WAC) in the 340B price column which means your Covered Entity may be paying full price while using 340B accumulations.

Before proceeding, consult with your legal counsel if needed, partner with your contract pharmacy and/or review your Pharmacy Services Agreements (PSA) for more information.

There are a few capabilities within 340B Architect that your facility can use:

Option 1 – Add NDCs to the Do Not Order list
This will prevent orders from splitting to the 340B account but will still allow claims to qualify for 340B.

Option 2 – Add NDCs to Exclude Items/340B Eligibility
This will prevent any claims from qualifying for 340B. Orders will still split to the 340B account if accumulations are present.

Option 3 – Add NDCs to both Do Not Order and Exclude Items/340B Eligibility
This combination of the above options will both prevent ordering and qualifications on 340B.

Contact your wholesaler for any questions about pricing. You may also consider referring to 340B Health and HRSA for additional information and resources.